
Is Novo Nordisk Stock a Buy After its Collapse?
As a pioneer in diabetes care, Novo Nordisk NOVO B claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion. Until 24 March, Novo Nordisk also claimed the throne as Europe …